DRUG UTILIZATION EVALUATION OF ANTIDIABETIC DRUGS AMONG TYPE 2 DIABETES PATIENTS OF TAMIL NADU

Geetha P; Shanmugasundharam P

doi:10.22159/ajpcr.2017.v10i9.19342

Authors

Geetha P Department of Pharmacy Practice, Faculty of Pharmacy, Vels University (VISTAS), Tamil Nadu, India.
Shanmugasundharam P Department of Pharmacy Practice, Faculty of Pharmacy, Vels University (VISTAS), Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i9.19342

Keywords:

Antidiabetic drugs, Oral hypoglycemic drug, Prescribing pattern

Abstract

Objectives: The aim of the study was to assess the prescribing pattern of antidiabetic drugs in Type 2 diabetes outpatients visiting to Diabetes Centre, Chennai.

Methods: A prospective study was carried out by evaluating 115 prescriptions of antidiabetic drugs over the period of 4 months to assess the prescribing pattern of antidiabetic drugs and also drugs used for other complications of Type 2 DM.

Results: Totally, 115 patients were evaluated, 58 were of male and 57 were of female. An average number of drugs per encounter were found to be 4.47. An average number of antidiabetic drugs were found to be 2.56. In this study, the most commonly prescribed oral hypoglycemic drug class as single-drug regimen was that of alpha-glucosidase inhibitors (16.326%), dipeptidyl peptidase-4 (DPP-4) inhibitors (14.62%), biquanides (12.9%), thiazolidine diones (9.8%), sulfonyl urea (7.82%) and meglitinides (2.38%), and in multi drug regimen metformin + alpha-glucosidase inhibitors (11.56%) were commonly prescribed.

Conclusion: Most commonly used drug was alpha-glucosidase inhibitors, followed by DPP-4 inhibitors and biguanides. All the patients received combination therapy to achieve the glycemic control.

Downloads

Download data is not yet available.

Author Biography

Geetha P, Department of Pharmacy Practice, Faculty of Pharmacy, Vels University (VISTAS), Tamil Nadu, India.

school of Pharmaceutical sciences, Vels university, Chennai.

References

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2013;36 Suppl 1:11-66.

WHO, Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Geneva, Switzerland: World Health Organization; 1999. p. 31-3.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes-estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(3):1047-53.

Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94(3):311-21.

Vengurlekar S, Shukla P, Patidar P, Bafna R, Jain S. Prescribing pattern of antidiabetic drugs in Indore city hospital. Indian J Pharm Sci 2008;70(5):637-40.

Rani J, Reddy S. Prescribing pattern of antidiabetic drugs in urban population of Hyderabad. Natl J Physiol Pharm Pharmacol 2015;5(1):5-9.

Haghighatpanah M, Thunga G, Jha A, Mallayasamy S. Study on prescrining pattern of anti-diabetic drugs among the 2 diabetes patients with complications in South Indian teaching hospital. Asian J Pharm Clin Res 2016;9(1):194-7.

Brian OO, Charles CE. Drug use indicators in patients with Type 2 diabetes in a tertiary health care facility in Nigeria. Int J Pharm Sci 2014;6(11):493-5.

Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk of myocardial infraction in Type 2 diabetic patients:meta analysis of seven long-term studies. Eur Heart J 2004;25(1):10-6.

Chiasson JL, Josse RG, Hanefeld M, Laakso MK. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. J Am Med Assoc 2003;290(4):486-94.

Talaviya PA, Saboo BD, Dodiya HG, Rao SK, Joshi SR, Modh VB, et al. Retrospective comparision of voglibose or acarbose as an add-on therapy to sulphonylureas in Western Indian patients with uncontrolled overweight/obese Type 2 diabetes. Diabetes Metab Syndr 2016;10(2):88-91.

Oishi M, Yamazaki K, Okuguchi F, Sugimoto H, Kanatsuka A, Kashiwagi A, et al. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32). J Diabetes Investig 2014;5(5):581-7.

Hampp C, Borders-Hemphill V, Money DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 003-2012. Diabetes Care 2014;37(5):1367-74.

Zaharan NL, Williams D, Bennett K. Prescibing of antidiabetic therapies in Ireland: 10 year trends 2003-2012. Ir J Med Sci 2014;183(2):311-8.

Marwa K, Tolba A, EL Khashab KA, Said AS. The effect of dipeptidyl peptidase -4 inhibitors on cardiovascular disease risk in Type 2 diabetes mellitus. Int J Pharm Sci 2017;9(1):254-9.

Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in Type 2 diabetes: A patient centered approach. Position statement of the American diabetes association (ADA) AND THE European association for the study of diabetes (EASD). Diabetologia 2012;55:1577-96.

American Diabetes Association. 7. Approches to glycemic treatment. Diabetes Care 2016;39 Suppl 1:S52-9.

Baviera M, Monesi L, Marzona I, Avanzini F, Monesi G, Nobili A, et al. Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italyâ€™s Lombardy region: A large population-based study. Diabetes Res Clin Pract 2011;93(1):123-30.

Chang CH, Jiang YD, Chung CH, Ho LT, Chuang LM. National trends in anti-diabetic treatment in Taiwan, 2000-2009. J Formos Med Assoc 2012;111(11):617-24.

Leal I, Romio SA, Schuemie M, Oteri A, Sturkenboom M, TrifirÃ² G. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: A focus on the effects of safety warnings about rosiglitazone. Br J Clin Pharmacol 2013;75(3):861-8.

Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of Type 2 diabetes in the U.S., 1997-2012. Diabetes Care 2014;37(4):985-92.

Lipska KJ, Ross JS, Wang Y, Inzucchi SE, Minges K, Karter AJ, et al. National trents in US hospital admissions for hypoglycemia and hypoglycemia among Medicare beneficiaris, 1999 to 2011. JAMA Intern Med 2014;174(7):1116-24.